CG Oncology is a clinical-stage biopharmaceutical company headquartered in Irvine, California, specializing in the development of oncolytic immunotherapies. The company is focused on creating innovative treatments for patients with bladder cancer and other solid tumor types, employing novel immunotherapies, including an oncolytic virus. Arthur Kuan leads CG Oncology as the Chairman & Chief Executive Officer, contributing his expertise from a strong background in healthcare investment and operational roles within the medical technology sector. The company's business model revolves around researching, acquiring, and developing next-generation immunotherapies, with a significant emphasis on clinical trials and collaborations to bring new cancer treatments to market